Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Gruber

Showing results (211-220 of 355) with videos related to

Pageof 36
Sort By:
Pediatrics|October 4, 2024
Safety of a 4-Dose 20-Valent Pneumococcal Conjugate Vaccine Series in Infants: A Randomized TrialGabriella Hajdu, Teena Hughes, G Laïssa Ouedraogo, et al.
Human Vaccines & Immunotherapeutics|March 1, 2014
Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults: a randomized open-label trialChristine Juergens, Pierre J T de Villiers, Keymanthri Moodley, et al.
Glia|September 20, 2017
Loss of Gas6 and Axl signaling results in extensive axonal damage, motor deficits, prolonged neuroinflammation, and less remyelination following cuprizone exposureAlex K Ray, Juwen C DuBois, Ross C Gruber, et al.
Vaccine|May 27, 2023
Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adults ≥65 years oldDavid Fitz-Patrick, Mariano Young, Kari Yacisin, et al.
Vaccine|April 15, 2024
Equivalent immunogenicity across three RSVpreF vaccine lots in healthy adults 18-49 years of age: Results of a randomized phase 3 studyJeffrey Baker, Negar Aliabadi, Iona Munjal, et al.
Vaccine|January 12, 2013
13-Valent pneumococcal conjugate vaccine (PCV13) in children partially immunized with 7-valent pneumococcal conjugate vaccine (PCV7): a phase 3, open-label trialSven Arne Silfverdal, Carl-Erik Flodmark, Lars Rombo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 15, 2015
Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged ≥2 years: an open-label studyCatherine Cordonnier, Per Ljungman, Christine Juergens, et al.
The Journal of Biological Chemistry|November 29, 2012
The 2.5 Å structure of the enterococcus conjugation protein TraM resembles VirB8 type IV secretion proteinsNikolaus Goessweiner-Mohr, Lukas Grumet, Karsten Arends, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 11, 2017
Lethality of MalE-LacZ hybrid protein shares mechanistic attributes with oxidative component of antibiotic lethalityNoriko Takahashi, Charley C Gruber, Jason H Yang, et al.
Human Vaccines & Immunotherapeutics|November 11, 2022
Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal diseaseCharu Sabharwal, Vani Sundaraiyer, Yahong Peng, et al.
Pageof 36

Showing results (211-220 of 355) with videos related to

Sort By:
Pageof 36
Pediatrics|October 4, 2024
Safety of a 4-Dose 20-Valent Pneumococcal Conjugate Vaccine Series in Infants: A Randomized TrialGabriella Hajdu, Teena Hughes, G Laïssa Ouedraogo, et al.
Human Vaccines & Immunotherapeutics|March 1, 2014
Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults: a randomized open-label trialChristine Juergens, Pierre J T de Villiers, Keymanthri Moodley, et al.
Glia|September 20, 2017
Loss of Gas6 and Axl signaling results in extensive axonal damage, motor deficits, prolonged neuroinflammation, and less remyelination following cuprizone exposureAlex K Ray, Juwen C DuBois, Ross C Gruber, et al.
Vaccine|May 27, 2023
Randomized trial to evaluate the safety, tolerability, and immunogenicity of a booster (third dose) of BNT162b2 COVID-19 vaccine coadministered with 20-valent pneumococcal conjugate vaccine in adults ≥65 years oldDavid Fitz-Patrick, Mariano Young, Kari Yacisin, et al.
Vaccine|April 15, 2024
Equivalent immunogenicity across three RSVpreF vaccine lots in healthy adults 18-49 years of age: Results of a randomized phase 3 studyJeffrey Baker, Negar Aliabadi, Iona Munjal, et al.
Vaccine|January 12, 2013
13-Valent pneumococcal conjugate vaccine (PCV13) in children partially immunized with 7-valent pneumococcal conjugate vaccine (PCV7): a phase 3, open-label trialSven Arne Silfverdal, Carl-Erik Flodmark, Lars Rombo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 15, 2015
Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged ≥2 years: an open-label studyCatherine Cordonnier, Per Ljungman, Christine Juergens, et al.
The Journal of Biological Chemistry|November 29, 2012
The 2.5 Å structure of the enterococcus conjugation protein TraM resembles VirB8 type IV secretion proteinsNikolaus Goessweiner-Mohr, Lukas Grumet, Karsten Arends, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 11, 2017
Lethality of MalE-LacZ hybrid protein shares mechanistic attributes with oxidative component of antibiotic lethalityNoriko Takahashi, Charley C Gruber, Jason H Yang, et al.
Human Vaccines & Immunotherapeutics|November 11, 2022
Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal diseaseCharu Sabharwal, Vani Sundaraiyer, Yahong Peng, et al.
Pageof 36